Clinical Trials

Eligibility Criteria: Patients with RA will be included if they meet the following criteria:

1. Adult patients ≥ 18 years of age.
2. Fulfillment of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA).
3. Fulfillment of the definition of inadequate response to previous DMARD therapy, according to the following criteria:
   1. Previous treatment for at least 3 months with at least 1 of the following conventional synthetic DMARDs: methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine.
   2. Previous treatment (any duration) with no greater than 3 biologic or targeted synthetic DMARDs (see list below) is acceptable.
   3. Moderate-to-high disease activity as defined by the Disease Activity Score 28, 4-variable version, using the C-reactive protein (DAS28-CRP) of ≥3.2.
4. Starting an eligible biologic or targeted synthetic DMARD, including one of the following medications:
   1. TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, or infliximab)
   2. Abatacept (Orencia; IV or SC)
   3. Tocilizumab (Actemra; IV or SC)
   4. Rituximab (Rituxan; IV)
   5. Tofacitinib (Xeljanz)
5. Prednisone therapy is acceptable if at a dose of ≤10 mg/day for the prior 2 weeks.